Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Cognition Therapeutics Announces Pricing of Public Offering
-
Triple Flag and Maverix to Combine: Building the Next Senior Precious Metals Streaming and Royalty Company
-
TRIPLE FLAG AND MAVERIX TO COMBINE: BUILDING THE NEXT SENIOR PRECIOUS METALS STREAMING AND ROYALTY COMPANY
-
Orchid Island Capital Announces November 2022 Monthly Dividend and October 31, 2022 Rmbs Portfolio Characteristics
-
Electra Announces Pricing of Public Equity Offering
-
SCYNEXIS (SCYX) PT Lowered to $15 at Cantor Fitzgerald
-
Liquid Meta Announces Upcoming Conference Participation
-
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
-
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
-
Electra Announces Marketed Offering of Units for Proceeds of up to approximately US$8 Million to Finance Commissioning of Cobalt Refinery
-
Cantor Fitzgerald Reiterates Overweight Rating on MannKind (MNKD); '3Q22 A Vote of Confidence in Long-Term Outlook'
-
AxoGen, Inc. (AXGN) PT Lowered to $18 at Cantor Fitzgerald
-
Riot Blockchain (RIOT) Rises as Other Miners Fall - Cantor Fitzgerald
-
Form SC 13G Healthwell Acquisition Filed by: CANTOR FITZGERALD SECURITIES
-
Curaleaf (CURLF) PT Lowered to $13 at Cantor Fitzgerald
-
BNP Paribas set to expand Exane in the U.S
-
Roivant Sciences (ROIV) Prices 30M Share Primary and Secondary Offering at $5/sh
-
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
-
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
-
Marinus Pharma (MRNS) Prices 10.53M Share Offering at $4.75/sh
-
Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering
-
Marinus Pharma (MRNS) Announces Proposed Public Offering
-
Marinus Pharmaceuticals Announces Proposed Public Offering
-
Roivant Sciences (ROIV) Announces Proposed Stock Offering, Size not Disclosed
-
Roivant Sciences Announces Proposed Public Equity Offering
-
Roivant Sciences Announces Proposed Public Equity Offering
-
Eagle Pharmaceuticals (EGRX) PT Lowered to $37 at Cantor Fitzgerald
-
FDA staff flags uncertainties on Veru's COVID drug; EUA hopes lift shares
-
Avalo Therapeutics Inc. (AVTX) PT Raised to $10 at Cantor Fitzgerald
-
RedHill Biopharma (RDHL) Provides H1'22 Highlights and Q3 Estimates
-
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
-
Canopy Growth Corp (CGC) PT Raised to $3.30 at Cantor Fitzgerald
-
Paya Holdings (PAYA) PT Raised to $9 at Cantor Fitzgerald
-
Applied Blockchain Announces Upcoming Conference Participation
-
Cantor Fitzgerald Remains Positive in Zoetis Inc. (ZTS) Growth Prospects Despite Marco Headwinds
-
Riot Blockchain (RIOT) produced 509 BTC in Oct.
-
Riot Announces October 2022 Production and Operations Updates
-
Riot Announces October 2022 Production and Operations Updates
-
Abeona Therapeutics (ABEO) Prices 7.6M Share Private Placement at $4.6/sh
-
Abeona Therapeutics Announces $35 Million Private Placement Financing
-
Abeona Therapeutics Announces $35 Million Private Placement Financing
-
Form SC 13G Healthcare AI Acquisitio Filed by: CANTOR FITZGERALD SECURITIES
-
Form SC 13G Ahren Acquisition Corp. Filed by: CANTOR FITZGERALD SECURITIES
-
Form SC 13G BioPlus Acquisition Corp Filed by: CANTOR FITZGERALD SECURITIES
-
UPDATE: Cantor Fitzgerald Starts Sorrento Therapeutics (SRNE) at Overweight
-
Form 8-K Cantor Fitzgerald Income For: Oct 31
-
Eli Lilly (LLY) Drops After Cutting Guidance, BMO Says Buy the Dip
-
Pfizer (PFE) Gains as Covid-19 Vaccine Drives a Beat, Analyst Sees Upside Potential
-
Bitfarms Provides October 2022 Production and Mining Operations Update
-
Bitfarms Provides October 2022 Production and Mining Operations Update


